Clinical trial
Bevacizumab in Treating Patients With Angiosarcoma
NCT00288015 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00288015 |
|---|---|
| Title | Bevacizumab in Treating Patients With Angiosarcoma |
| Official title | An Open Label Multicenter Phase II Study of Bevacizumab for the Treatment of Angiosarcoma |
| Lead sponsor | Northwestern University, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Biological |
| Interventions | Bevacizumab |
| Enrollment | 32 |
| Start date | Oct 1, 2005 |
| Primary completion | Jun 6, 2013 |
| Completion | Nov 10, 2016 |
| First posted | Feb 7, 2006 |
| Last update posted | Jun 25, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: